On June 25, 2013, MAPS submitted for review by a Canadian Institutional Review Board an amended protocol and other study documents for our upcoming Canadian study of MDMA-assisted psychotherapy for PTSD. Both Health Canada and the Canadian IRB have already approved this study. We are now requesting several changes to the study design to complement our other ongoing studies around the world, including changes to dose levels, the schedule of subject visits, and the timing of treatment outcome assessments. Aligning our study protocols across sites enables us to compare data and make a stronger case for future Phase 3 studies.
